Comments on the potential abuse and medical usefulness of a range of substances including CBD will be submitted to the World Health Organization (WHO) by the US Food and Drug Administration (FDA) and its parent government department.

The comments will be used by the WHO to determine recommendations on international restrictions for 16 substances. They include cannabis plants and resin as well as extracts and tinctures of cannabis, which would include CBD, as well as THC and related compounds.

In order to develop its response, the FDA is currently requesting informed comments, which should be submitted by the end of October.

Comments received by the FDA and the US Department of Health and Human Services (HHS) will be considered by the HHS in preparing a scientific and medical evaluation for drug substances to be forwarded to the WHO.

Read full article
I'm already a subscriber

Freddie Dawson

Managing editor, news
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the ECigIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization